Welcome to our dedicated page for Reviva Pharmaceuticals Holdings news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. will present new non-clinical pharmacology data on brilaroxazine at the ASPET 2024 Annual Meeting. The data will focus on drug transporter interaction and absorption, metabolism, and excretion in rats. The presentations will be held on May 19, 2024, by Founder and CEO Laxminarayan Bhat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.11%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals gains FDA alignment for brilaroxazine clinical trials in schizophrenia, with potential NDA support. Topline data from long-term safety study expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported successful results from the RECOVER-1 Phase 3 trial for brilaroxazine in schizophrenia, with plans to initiate the RECOVER-2 trial in 2024. The company expects to submit a New Drug Application (NDA) in 2025. Financially, the net loss for 2023 was $39.3 million, compared to $28.3 million in 2022, with cash and equivalents at $23.4 million in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announces Dr. Laxminarayan Bhat's presentation at the 2024 SIRS Annual Meeting in Italy regarding Brilaroxazine Phase 3 Recover Trial in Acute Schizophrenia, showcasing efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that their CEO will present a poster at the ASCPT 2024 Annual Meeting on Brilaroxazine Efficacy in the Phase 3 RECOVER Trial for Acute Schizophrenia. The presentation will focus on addressing unmet medical needs in CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.97%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that their CEO will participate in a Fireside Chat at the UBS Virtual CNS Day on March 18, 2024, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that its Founder, President, and CEO will present at the 36th Annual ROTH Conference to discuss the company's late-stage pharmaceutical developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that its CEO will present at the 2024 BIO CEO & Investor Conference in New York, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will host a virtual event on February 15, 2024, featuring key opinion leaders discussing the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia. The event will focus on the positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the participation of its CEO in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host virtual one-on-one meetings with investors. The webcasted fireside chat will take place on February 1, 2024, and will be available for replay. Management will be participating in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Reviva Pharmaceuticals Holdings (RVPH)?
The current stock price of Reviva Pharmaceuticals Holdings (RVPH) is $1.24 as of November 21, 2024.
What is the market cap of Reviva Pharmaceuticals Holdings (RVPH)?
The market cap of Reviva Pharmaceuticals Holdings (RVPH) is approximately 40.5M.
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Reviva Pharmaceuticals specializes in discovering, developing, and commercializing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases.
Where is Reviva Pharmaceuticals Holdings, Inc. located?
The company is located at 5941 Optical Ct, San Jose, California, United States.
What is Brilaroxazine (RP5063)?
Brilaroxazine (RP5063) is a versatile drug candidate intended to treat multiple neuropsychiatric conditions including schizophrenia, bipolar disorder, and Parkinson's disease psychosis, among others.
What is the focus of Reviva's current pipeline?
Reviva's current pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases.
What technology does Reviva use for drug development?
Reviva Pharmaceuticals utilizes a chemical genomics-driven technology platform and proprietary chemistry for drug development.
Who can be contacted for more information about Reviva Pharmaceuticals?
For more information, you can contact Reviva Pharmaceuticals Holdings, Inc., their Investor Relations at LifeSci Advisors, or their Media Contact, Kristin Polit.
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
Another drug candidate in Reviva's pipeline is RP1208.
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
Reviva Pharmaceuticals targets therapeutic areas within the central nervous system, inflammatory, and cardiometabolic diseases.
How can I stay updated with Reviva Pharmaceuticals' latest news?
You can visit their official website or subscribe to updates through their corporate and investor relations contacts.
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
The main contact for investor inquiries is Bruce Mackle from LifeSci Advisors, LLC.
Reviva Pharmaceuticals Holdings, Inc.
Nasdaq:RVPH
RVPH Rankings
RVPH Stock Data
40.46M
28.50M
14.79%
30.07%
15.84%
Biotechnology
Pharmaceutical Preparations
United States of America
CUPERTINO